Drug Profile
Research programme: inflammation therapy - Chiesi USA
Alternative Names: Anti-HMBG1 Mab; Anti-HMGB-1 MAbLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Critical Therapeutics
- Developer Chiesi USA
- Class Monoclonal antibodies
- Mechanism of Action High mobility group protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Inflammation; Rheumatoid arthritis; Septic shock
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Septic-shock in USA (Parenteral)